Regulatory approval

Published by the Health Service Executive. Approved

As monotherapy is indicated for the treatment of locally advanced or metastatic urothelial carcinoma in adults who are not eligible for cisplatin-containing chemotherapy whose tumours express PD-L1 with a combined positive score (CPS) >= 10.

This is written in the approval document.

Reimbursement

ODMS

Citation

Pembrolizumab 400mg Monotherapy, 2024, version number 13, NCCP National SACT Regimen, NCCP, viewed 02/08/2026, https://healthservice.hse.ie/documents/6389/558_v12b_Pembrolizumab_400mg_monotherapy.pdf

Therapeutic response

Precision oncology relationships for therapeutic response derived from this regulatory approval.

Organizations	Biomarkers	Cancer types	Therapies
HSE (1)	PD-L1 (CPS) >= 10	Bladder Urothelial Carcinoma	Pembrolizumab

Contributions

Date	Contributor	Description
2024-01-16	Van Allen lab	Adding HSE approvals for reimbursement to database
2021-02-01	Health Service Executive	Indication approved for reimbursement.